These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37967254)

  • 1. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
    Parikh R; Singer D; Chmielewski-Yee E; Dessart C
    Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
    Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
    Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
    Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
    Giannelos N; Ng C; Curran D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.
    Xia Y; Zhang X; Zhang L; Fu C
    Front Immunol; 2022; 13():978203. PubMed ID: 36248796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes zoster in Belgium: a new solution to an old problem.
    Nikkels AF; Schoevaerdts D; Kauffmann F; Strubbe F; Bensemmane S
    Acta Clin Belg; 2024 Jun; 79(3):205-216. PubMed ID: 38781037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients.
    Racine É; Gilca V; Amini R; Tunis M; Ismail S; Sauvageau C
    Vaccine; 2020 Sep; 38(40):6205-6214. PubMed ID: 32788132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
    Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
    Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
    Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
    Safonova E; Yawn BP; Welte T; Wang C
    Respir Res; 2023 Jan; 24(1):35. PubMed ID: 36709298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
    Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
    J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
    Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
    Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.